恶性黑素瘤,嵌合型抗原受体T细胞,肿瘤免疫微环境," /> 恶性黑素瘤,嵌合型抗原受体T细胞,肿瘤免疫微环境,"/> malignant melanoma, chimeric antigen receptor T cells, tumor immune microenvironment,"/> Update of chimeric antigen receptor T cell in malignant melanoma

China Journal of Leprosy and Skin Diseases ›› 2024, Vol. 40 ›› Issue (1): 59-65.doi: 10.12144/zgmfskin202401059

• Reviews • Previous Articles     Next Articles

Update of chimeric antigen receptor T cell in malignant melanoma

ZHANG Likun1, YUE Wuheng2, ZOU Zhengyun3   

  1. 1 Department of Dermatology，Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine，Taicang 215400, China; 2 Department of Oncology, Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine，Taicang 215400, China; 3 The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China
  • Online:2024-01-15 Published:2023-12-25

PDF (PC)

74

Like

Abstract: There are a variety of biomarkers expressed on the membrane of malignant melanoma cells, which can be used as therapeutic targets to develop targeted chimeric antigen receptor T cells (CAR-T). CAR-T has shown good effects on GD2, HER2, CD70, Gp100, NYESO-1 and other targets in malignant melanoma. This paper aims to review the targets and clinical progress of CAR-T cells for malignant melanoma, and analyze the challenges and countermeasures of engineered T cells, in order to apply CAR-T cells to the clinical practice of malignant melanoma.

Key words: malignant melanoma')">">malignant melanoma, chimeric antigen receptor T cells, tumor immune microenvironment